Agonists of GLP-1 receptors (GLP-1 RAs) such as liraglutide, dulaglutide and semaglutide have been shown to achieve substantial glycaemic control and facilitate weight reduction, and have been used for the management of T2D and obesity with excellent results [11,12]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.